A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00446602
Recruitment Status : Withdrawn (Due to company decision to focus resources on a larger, controlled study in this patient population.)
First Posted : March 13, 2007
Last Update Posted : September 20, 2016
Ortho Biotech Clinical Affairs, L.L.C.
Information provided by:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Primary Completion Date : No date given
  Estimated Study Completion Date : August 2009